NDA 020479 · Viatris Specialty
Gastrocrom
Cromolyn Sodium · Oral
OrphanLast checked: Nov 20, 2026Latest source record: Feb 13, 2003 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Feb 29, 1996
Approved uses
1
Original approval plus efficacy supplements
Registered trials
30
7 Phase 3, 4 recruiting
FAERS reports
3,311
1,201 serious, 38 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 26, 2024.
INDICATIONS AND USAGE GASTROCROM is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients.
Therapeutic areas: Gastroenterology and liver
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 29, 1996 Original approval · Type 3 - New Dosage Form
1 products under this application
- GASTROCROM · CROMOLYN SODIUM 100MG/5ML · CONCENTRATE, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Cromolyn" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's DiseasePivotal-lookingCompleted
AZTherapies, Inc.Industry
NCT02547818 · 620 participants · Start Sep 15, 2015 · Primary completion Nov 13, 2020
Drug: ALZT-OP1a; ALZT-OP1b · For: Alzheimer's Disease
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 121 sites in all
- Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma (0476-232)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00943397 · 190 participants · Start Apr 2001 · Primary completion Oct 2001
Drug: montelukast sodium; Comparator: Usual Care · For: Asthma
- Cromoglicate Adjunctive Therapy for Outpatients With SchizophreniaPivotal-lookingRecruiting
Vishwajit Nimgaonkar, MD PhDAcademic, hospital or other
NCT03794076 · 160 participants (planned) · Start Apr 1, 2019 · Primary completion Jan 2028
Drug: Cromoglycate; Placebo · For: Schizophrenia; Schizo Affective Disorder
Sites: Pittsburgh, Pennsylvania
- Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic TreatmentPivotal-lookingStatus unknown
AB ScienceIndustry
NCT04333108 · 140 participants (planned) · Start Jul 1, 2020 · Primary completion Dec 2024
Drug: Masitinib · For: Indolent Systemic Mastocytosis
Sites: Amiens, France; Besançon, France; Grenoble, France · 17 sites in all
- Masitinib in Severe Indolent or Smoldering Systemic MastocytosisPivotal-lookingCompleted
AB ScienceIndustry
NCT00814073 · 135 participants · Start Dec 2008 · Primary completion Nov 2015
Drug: Masitinib; Placebo · For: Indolent Systemic Mastocytosis
Sites: Sacramento, California; Houston, Texas; Amiens, France · 24 sites in all
- PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALSPivotal-lookingRecruiting
PhenoNet, Inc.Industry
NCT07142291 · 105 participants (planned) · Start Nov 25, 2025 · Primary completion Mar 2027
Drug: Cromolyn Sodium (34.2 mg BID); Cromolyn Sodium (17.1 mg BID) and 2 more · For: Amyotrophic Lateral Sclerosis (ALS)
Sites: Scottsdale, Arizona; La Jolla, California; San Francisco, California · 22 sites in all
Fudan UniversityAcademic, hospital or other
NCT05076682 · 90 participants (planned) · Start Jun 30, 2022 · Primary completion Dec 31, 2026
Drug: Choline; anti-PD-1 antibody and chemotherapy and 9 more · For: Triple-negative Breast Cancer
Sites: Shanghai, China
AB ScienceIndustry
NCT05449444 · 72 participants (planned) · Start Jul 1, 2022 · Primary completion Dec 31, 2024
Drug: Masitinib 4.5 mg/kg/day; Placebo and 1 more · For: Mast Cell Activation Syndrome
Sites: Weldon Spring, Missouri; Amiens, France; Paris, France · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- treatment failure1,006
- drug ineffective301
- fatigue204
- nausea193
- headache168
- off label use164
- diarrhoea160
- urticaria147
- dyspnoea130
- anaphylactic reaction127
- pruritus124
- pain122
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 28 |
| 2005 | 24 |
| 2006 | 17 |
| 2007 | 20 |
| 2008 | 28 |
| 2009 | 44 |
| 2010 | 39 |
| 2011 | 45 |
| 2012 | 26 |
| 2013 | 16 |
| 2014 | 25 |
| 2015 | 40 |
| 2016 | 85 |
| 2017 | 65 |
| 2018 | 70 |
| 2019 | 104 |
| 2020 | 1,101 |
| 2021 | 139 |
| 2022 | 212 |
| 2023 | 256 |
| 2024 | 317 |
| 2025 | 346 |
| 2026 | 264 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Current · updated Nov 18, 2026
Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96).
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Gastrocrom (Cromolyn Sodium)
2024 spending
$1.0M
Beneficiaries
81
291 claims
Per beneficiary
$12,890
$2.21 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $458,010 |
| 2021 | $459,042 |
| 2022 | $539,009 |
| 2023 | $663,437 |
| 2024 | $1,044,112 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cromolyn.
Berman BA, Ross RN · Clin Rev Allergy 1983 · Clinical Trial, Review
- Pharmacological interventions for pruritus in adult palliative care patients.
Boehlke C, Joos L, Coune B, et al. · Cochrane Database Syst Rev 2023 · Meta-Analysis, Systematic Review
- Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial.
Wu SY, Jin X, Liu Y, et al. · Nat Med 2025 · Clinical Trial, Phase II
- Ocular allergy and mast cell stabilizers.
Allansmith MR, Ross RN · Surv Ophthalmol 1986 · Clinical Trial, Research Support, U.S. Gov't, P.H.S.
- Systematic Review and Meta-Analysis of Randomised, Other-than-Placebo Controlled, Trials of Non-Individualised Homeopathic Treatment.
Mathie RT, Fok YYY, Viksveen P, et al. · Homeopathy 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- An evidence-based review of systemic treatments for itch.
Pongcharoen P, Fleischer AB · Eur J Pain 2016 · Meta-Analysis, Systematic Review
Sponsor: Viatris Specialty
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.